Alzheimer's Linked to High Plasma Homocysteine Levels

Share this content:
Alzheimer's Linked to High Plasma Homocysteine Levels
Alzheimer's Linked to High Plasma Homocysteine Levels

HealthDay News — Plasma homocysteine (HC) and its metabolite homocysteine thiolactone (HCTL) contribute to Alzheimer's disease (AD) pathology via the amyloid-β (Aβ)-fibrinogen interaction, according to a study published in the Journal of Thrombosis and Haemostasis.

Young Cheul Chung, from Rockefeller University in New York City, and colleagues examined the specific role of elevated homocysteine levels in AD pathophysiology. Immunohistochemistry, cerebral amyloid angiopathy (CAA), fibrinogen deposition, and their correlation to each other were examined in the brains of AD patients with and without hyperhomocysteinemia (HHC). An AD mouse model was administered a high methionine diet for several months to study AD-HCC comorbidity in detail.

In AD patients with HHC, the researchers identified increased fibrinogen levels and amyloid-β (Aβ) deposits in the blood vessels and brain parenchyma. HC and HCTL were found to enhance the interaction between fibrinogen and Aβ, promote tighter fibrin clot formation, and delay fibrinolysis of clots. In an AD mouse model, diet-induced HHC led to severe CAA and parenchymal Aβ deposition, and to significant impairments in learning and memory.

"These findings suggest that elevated levels of plasma HC/HCTL contribute to AD pathology via the Aβ-fibrinogen interaction," the authors write.


Chung YC, Kruyer A, Yao Y, et al. Hyperhomocysteinemia exacerbates Alzheimer's disease pathology by way of the Aβ-fibrinogen interaction. J Thromb Haemost. 2016; doi:10.1111/jth.13340.

You must be a registered member of Neurology Advisor to post a comment.

Next Article in Neurodegenerative Diseases

Sign Up for Free e-newsletters

CME Focus